In vitro activity of ceftazidime/avibactam against Gram-negative pathogens isolated from pneumonia in hospitalised patients, including ventilated patients

International Journal of Antimicrobial Agents

Volumn 47, Issue 3, 2016, Pages 235-242

  Flamm, Robert K ^a   Nichols, Wright W ^b   Sader, Helio S ^a   Farrell, David J ^a   Jones, Ronald N ^a,c  

^a JMI LABORATORIES   (United States)

^b ASTRAZENECA   (United Kingdom)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Ceftazidime avibactam; Hospital acquired pneumonia; Ventilator associated pneumonia

Indexed keywords

AMIKACIN; AVIBACTAM PLUS CEFTAZIDIME; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; COLISTIN; GENTAMICIN; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; ANTIINFECTIVE AGENT; AVIBACTAM; AZABICYCLO DERIVATIVE;

ACINETOBACTER; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL PNEUMONIA; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CHINA; CONTROLLED STUDY; DRUG SCREENING; ENTEROBACTER; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; HOSPITAL ACQUIRED PNEUMONIA; HOSPITAL PATIENT; HUMAN; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MIC50; MIC90; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SERRATIA; SOUTHERN EUROPE; STAPHYLOCOCCUS AUREUS; UNITED STATES; VENTILATED PATIENT; VENTILATOR ASSOCIATED PNEUMONIA; ARTIFICIAL VENTILATION; CROSS INFECTION; DRUG EFFECTS; GRAM-NEGATIVE BACTERIAL INFECTIONS; HOSPITALIZATION; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; PNEUMONIA, BACTERIAL;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; CEFTAZIDIME; CROSS INFECTION; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HOSPITALIZATION; HUMANS; MICROBIAL SENSITIVITY TESTS; PNEUMONIA, BACTERIAL; RESPIRATION, ARTIFICIAL;

EID: 84960446608     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2016.01.004     Document Type: Article

References (16)

1. G.G. Zhanel, C.D. Lawson, H. Adam, F. Schweizer, S. Zelenitsky, P.R. Lagace-Wiens, and et al. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination Drugs 73 2013 159 177
2. K. Coleman Diazabicyclooctanes: a potent new class of non-β-lactam β-lactamase inhibitors Curr Opin Microbiol 14 2011 550 555
3. R.K. Flamm, H.S. Sader, W.W. Nichols, and R.N. Jones Activity of ceftazidime-avibactam tested against hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia Gram-negative pathogens from the Europe-Mediterranean region, China, and USA 53rd Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), 10-13 September 2013 2013 ASM Press Denver, CO/Washington, DC [abstract C2-1629]
4. R.N. Jones Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia Clin Infect Dis 51 Suppl. 1 2010 S81 S87
5. F.M. Abrahamian, P.M. Deblieux, C.L. Emerman, M.H. Kollef, E. Kupersmith, K.V. Leeper Jr., and et al. Health care-associated pneumonia: identification and initial management in the ED Am J Emerg Med 26 2008 1 11
6. M.H. Kollef, A. Shorr, Y.P. Tabak, V. Gupta, L.Z. Liu, and R.S. Johannes Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia Chest 128 2005 3854 3862
7. P.G. Ambrose, S.M. Bhavnani, E.J. Ellis-Grosse, and G.L. Drusano Pharmacokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated bacterial pneumonia studies: look before you leap Clin Infect Dis 51 Suppl. 1 2010 S103 S110
8. ClinicalTrials.gov. A study comparing ceftazidime-avibactam versus meropenem in hospitalized adults with nosocomial pneumonia. NCT01808092. https://clinicaltrials.gov/ct2/show/NCT01808092 [accessed 27.01.16].
9. R.N. Jones Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: a five-year summary from the SENTRY Antimicrobial Surveillance Program (1997-2001) Semin Respir Crit Care Med 24 2003 121 134
10. A.C. Gales, H.H. Sader, and R.N. Jones Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia in Latin America: frequency of occurrence and antimicrobial susceptibility profile: results from the SENTRY Antimicrobial Surveillance Program (1997-2000) Diagn Microbiol Infect Dis 44 2002 301 311
11. D.J. Hoban, D.J. Biedenbach, A.H. Mutnick, and R.N. Jones Pathogen of occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: results of the SENTRY Antimicrobial Surveillance Study (2000) Diagn Microbiol Infect Dis 45 2003 279 285
12. R.N. Jones, M.A. Croco, K.C. Kugler, M.A. Pfaller, and M.L. Beach Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997) Diagn Microbiol Infect Dis 37 2000 115 125
13. Clinical and Laboratory Standards Institute Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard - ninth edition. Document M07-A9 2012 CLSI Wayne, PA
14. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing; twenty-third informational supplement. Document M100-S23 2013 CLSI Wayne, PA
15. European Committee on Antimicrobial Susceptibility Testing Breakpoint tables for interpretation of MICs and zone diameters, Version 3.0 2013, January EUCAST http://www.eucast.org/clinical-breakpoints/ [accessed 02.01.13]
16. Actavis Inc. Avycaz™ (ceftazidime-avibactam) prescribing information 2015 Actavis Inc. http://pi.actavis.com/data-stream.asp?product-group=1957&p=pi&language=E [accessed June 2015]